Technology

Not FDA cleared.

Not available in the United States.

MyoVista Image

HeartSciences’ MyoVista® Wavelet ECG (wavECG™) Cardiac Testing Device has been developed in response to the recent understanding that most forms of heart disease are associated with left ventricular (LV) relaxation abnormalities and left ventricular diastolic dysfunction (LVDD)¹. The MyoVista wavECG Device uses wavelet signal processing to extract frequency information from the acquired ECG signal which is then analyzed using artificial intelligence. This breakthrough innovation uses proprietary technology that is designed to be used by physicians as part of an overall heart disease risk assessment to assist in determining whether a patient should receive further testing, evaluation and/or treatment.

The MyoVista wavECG Device is a 12-lead resting electrocardiograph (ECG) device that features wavECG Technology plus the capabilities of a full featured conventional 12-lead resting ECG including analysis using the University of Glasgow Algorithm, one of the world’s most respected interpretive algorithms. The conventional ECG and MyoVista wavECG test results are displayed independently.

HeartScience’s MyoVista wavECG Device benefits from years of research and development by HeartSciences to improve the ability of electrocardiography to detect most forms of heart disease.

¹LV Diastolic Dysfunction and Prognosis, Dalane W. Kitzman, MD and William C. Little, MD AHA Circ 2012 Feb 14; 125(6): 743–745

Conventional ECG devices have known limitations:

Current conventional ECGs have limited sensitivity in identifying structural and ischemic heart disease. The MyoVista wavECG Device assists physicians in the detection of abnormal LV relaxation that may be caused by heart disease. The additional wavECG Information provided by the MyoVista Device may assist physicians in determining if a patient should receive further testing, evaluation and/or treatment.

Conventional Image
Diagnostic Image

Understanding the “Diagnostic Gap”

  • Most patients with heart disease are asymptomatic.
  • Physicians have limited front-line technology options to detect heart disease.
  • Most advanced diagnostic tests are expensive and require referral.
  • Nuclear Stress; Echocardiogram, CT Angiogram, are expensive tests that are not used as front-line tools
  • Payors often discourage advanced diagnostics for asymptomatic patients

Addressing the need for modern innovative low-cost cardiac testing tools

Statistics show that over 50% of patients find out they have heart disease through an adverse event*. Millions of people worldwide consider themselves to be healthy but are unaware they could be suffering from heart disease. They are living without symptoms, yet their heart tissue may already have signs of heart disease. HeartScience’s MyoVista wavECG Cardiac Testing Device has been developed in response to the recent understanding that most forms of heart disease are associated with left ventricular (LV) relaxation abnormalities and LV diastolic dysfunction. The wavECG Analysis Results are provided for physician review to assist in determining patient risk of left ventricular relaxation abnormalities. Current ECG technology is not designed to detect left ventricular relaxation abnormalities.

*Koskinas K. Appropriate use of non-invasive testing for diagnosis of stable coronary artery disease. E-Journal of Cardiology Practice. 2014;12(19). Retrieved from: https://www.escardio.org/Journals/E-Journal-of-Cardiology Practice/Volume-12/Appropriate-use-of-non-invasive-testing-for-diagnosis-of-stable-coronary-artery.

Ischemic Image
QRST Image

The MyoVista Energy Waveform is the ECG signal display after wavelet signal processing

  • Horizontal axis (x-axis) is time
  • Vertical axis (y-axis) is frequency
  • Frequencies range from 3 Hz (bottom) to 200 Hz (top)
  • Color scaling provides additional (non-linear) mapping of energy
  • Color represents a level of energy at each point in time and frequency
  • Blue represents low energy, red represents high energy

Advanced Signal Processing

HeartSciences uses continuous wavelet transform mathematics to extract the frequency content from the input ECG signal.  This additional valuable information is used as part of the input in developing the AI models and helps improve overall model performance. The waveform displayed on the device and in the video is called a scalogram and is a representation of the ECG waveform after wavelet signal processing. The scalogram provides a non-linear mapping of the frequency content in the waveform, depicting the energy in the waveform at each point in time and frequency. Blue represents low energy, red represents high energy, and intermediate energy levels are shown according to the levels of red, blue and green at any point in time. The MyoVista Energy Waveform graphically displays the energy distribution pattern of the heart’s electrical activity during each phase of the cardiac cycle. It is visually aligned with the conventional ECG trace.

 

Note: The MyoVista Energy Waveform is only displayed to provide visual context for the MyoVista wavECG Information and to assist with assessment of potential signal quality issues. The MyoVista Energy Waveform is not intended to be used for clinical assessment purposes.

MyoVista® wavECG™ LV Relaxation Algorithm Indicator and Statement

The MyoVista wavECG LV Relaxation Algorithm is calculated using AI-based algorithms which incorporate data from the transformed ECG signal using continuous wavelet signal processing as well as conventional ECG information.

The wavECG LV Relaxation Algorithm Result is provided in both indicator and statement form and displays the result as either “Highly Negative”, “Negative”, “Borderline”, “Positive” or “Highly Positive” for LV relaxation abnormality.

MyoVista Image
Analysis Image

Conventional ECG Trace with Interpretive Analysis

The MyoVista wavECG Device is a 12-lead resting electrocardiograph (ECG) device that features wavECG Technology plus the capabilities of a full featured conventional 12-lead resting ECG including analysis using the University of Glasgow Algorithm, one of the world’s most respected interpretive algorithms. The conventional ECG and MyoVista wavECG test results are displayed independently..

MyoVista Clinical Value

  • Non-invasive, standard 12-lead ECG testing protocol
  • Assists in detection of electrical heart disease as well as LV dysfunction that may be related to structural and/or ischemic heart disease
  • Overall wavECG Analysis categorizes potential risk of abnormal LV relaxation.
  • Includes conventional 12-lead ECG information and University of Glasgow Analysis Report in the same test

MyoVista Functional Value

  • Intuitive touch screen
  • Easy to perform
  • Follows conventional AHA/IEC lead placement ECG protocol
  • Data storage capacity = 100,000+ test records
  • EMR-EHR capable
  • Wi-Fi and USB printer enabled
  • PDF file exportable
  • High definition 1920 x 1080 display

MyoVista Economic Value

  • New heart disease risk stratification information using electrocardiography wavECG and conventional ECG results are provided as independent test results
  • Reimbursable- use of conventional resting 12-lead ECG coding
  • Quick: 20/30/60 second test with immediate results
  • PDF printing eliminates need for thermal recording chart paper
Value Image
Specification Image

Specifications

  • 15.6 Inch (396 mm) hi-res color LCD 1920 x 1080
  • Multi-gesture touch screen – nitrile glove compatible
  • Built-in desktop stand with 15 degree and 30 degree viewing angles
  • Stores over 100,000 test records
  • Solid State hard drive (SSD)
  • Sampling rate: 1000 samples/sec/channel
  • Patient Information: Patient ID, Name, Age, Sex, Height, Weight, BSA, and comments free form area.
  • RJ-45 Gigabit Ethernet
  • Dual band Wi-Fi 802.1 1ac 2.4 GHz, 5.2 GHz
  • Security: WEP, WPA, and WPA2 based encryption
  • External keyboard compatible
  • HDMI external monitor compatible
  • Wi-Fi printer enabled
  • Barcode enabled
  • EMR – EHR Capable
  • HL7 Capable